New Treatment for Aggressive B-Cell Lymphoma
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of medicines (Pola-R-CHP plus a new drug called Sonrotoclax) for newly diagnosed aggressive B-cell lymphoma, especially cases with high BCL-2 protein or double-hit features. The goal is to see if adding Sonrotoclax helps control the cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Recently diagnosed with large B-cell lymphoma confirmed by biopsy, not in the brain
- Age 18 to 75 years old
- Never received cancer treatment before (except steroids)
- Cancer has measurable tumors on imaging (lymph nodes or other areas)
- Able to handle treatment with good enough organ function (heart, liver, kidneys)
- No active infections, uncontrolled heart problems, or untreated TB
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding another drug (X) to a standard chemotherapy mix (Pola-RCHP) works better for people with untreated diffuse large B-cell lymphoma (DLBCL). It is for those whose cancer DNA levels did not drop enough after the first round of treatment.
This study tests a combination of four drugs (sonrotoclax, glofitamab, gemcitabine, and oxaliplatin) for people with large B-cell lymphoma that has come back or not responded to previous treatment. The goal is to see if this combination is safe and effective.
This trial tests a combination of three targeted drugs (polatuzumab vedotin, zanubrutinib, and R-CHP) for people newly diagnosed with a specific subtype of DLBCL called non-GCB. The goal is to see if this powerful mix can work better than standard treatment.
This study tests whether a new three-drug combination (Pola-ZR-Glo) works safely and effectively for older adults with a type of blood cancer called large B-cell lymphoma who cannot or prefer not to receive standard chemotherapy. The goal is to find a gentler treatment option for frail or elderly patients.
This trial tests a combination of targeted antibody drugs (polatuzumab vedotin and rituximab) plus two chemo drugs (gemcitabine and oxaliplatin) for people with DLBCL whose cancer returned after their first treatment and who cannot have a stem cell transplant. The goal is to see if this combination works better as a second-line treatment.
This trial tests a combination of three drugs (Polatuzumab, Rituximab, and Orelabrutinib) for elderly patients who are frail or over 80 with a specific type of untreated diffuse large B-cell lymphoma (non-GCB DLBCL). The goal is to see if this drug combo is safe and effective for those who may not tolerate standard chemotherapy.
Hear when a new Large B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.